Page 6 - Recursion Map News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Recursion map. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Recursion Map Today - Breaking & Trending Today

Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis


Share this article
Share this article
SALT LAKE CITY, May 25, 2021 /PRNewswire/  Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company has initiated investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile (C. difficile) infections and potential prophylactic use in high-risk patients.
REC-163964 is the first internally-discovered New Chemical Entity (NCE) development candidate identified by the Recursion Operating System and advanced to IND-enabling studies. This lead represents one of three structurally-differentiated candidates discovered by Recursion s ML-enabled Operating System for the potential treatment of C. difficile. ....

Chris Gibson , Elyse Freeman , Exchange Commission , Recursion Pharmaceuticals Inc , Recursion Pharmaceuticals , New Chemical Entity , Recursion Operating System , Operating System , Recursion Map , Securities Litigation Reform Act , கிறிஸ் கிப்சன் , பரிமாற்றம் தரகு , புதியது இரசாயன நிறுவனம் , இயங்குகிறது அமைப்பு , பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,

Recursion Pharmaceuticals Announces Pricing of Initial Public Offering


Recursion Pharmaceuticals Announces Pricing of Initial Public Offering
News provided by
Share this article
Share this article
SALT LAKE CITY, April 16, 2021 /PRNewswire/ Recursion Pharmaceuticals, Inc. ( Recursion or we ) today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Recursion, are expected to be $436.4 million, excluding any exercise of the underwriters option to purchase additional shares. The shares are expected to begin trading on the Nasdaq Global Select Market on April 16, 2021 under the symbol RXRX and the offering is expected to close on April 20, 2021, subject to customary closing conditions. In addition, Recursion has granted the underwriters a 30-day option to pur ....

New York , United States , Elyse Freeman , Broadridge Financial Solutions , Jp Morgan Securities , Allen Company , Prnewswire Recursion Pharmaceuticals Inc , Exchange Commission , Prospectus Department , Goldman Sachs Co , Recursion Pharmaceuticals , Nasdaq Global Select Market , Keybanc Capital Markets , Goldman Sachs , Island Avenue , Recursion Operating System , Recursion Map , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , பிராட்ரிட்ஜ் நிதி தீர்வுகள் , ஜ்ப் மோர்கன் பத்திரங்கள் , ஆலன் நிறுவனம் , பரிமாற்றம் தரகு , ப்ரோஸ்பெக்டஸ் துறை , கோல்ட்மேன் சாக்ஸ் இணை , நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை ,